Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease
Launched by SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · Jun 14, 2011
Trial Information
Current as of May 02, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age \> 18 years
- • male or un-pregnant female
- • stenosis \> 70% in one of major the epicardial coronary arteries
- • no contra-indications of stent implantation
- • singed the informed consent
- Exclusion Criteria:
- • acute myocardial infarction within one week
- • have contra-indications of stent implantation or can not tolerate dual antiplatelet therapy
- • no history of stent implantation within last one-year
- • received other brand coronary stent during index procedure
- • with no achievement of informed consent
About Shanghai Jiao Tong University School Of Medicine
Shanghai Jiao Tong University School of Medicine is a leading academic institution in China, renowned for its commitment to advancing medical research and education. As a prominent clinical trial sponsor, the school leverages its extensive expertise in biomedical sciences and innovative healthcare solutions to conduct rigorous clinical studies aimed at improving patient outcomes. With a focus on collaboration and translational research, the institution fosters partnerships with healthcare providers, industry leaders, and regulatory bodies to ensure the highest standards of scientific integrity and ethical conduct in clinical trials. Through its research initiatives, Shanghai Jiao Tong University School of Medicine strives to contribute significantly to the global medical community and enhance the quality of healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials